Linked Life Data

19481800

Source:http://linkedlifedata.com/resource/pubmed/id/19481800

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2010-2-1
pubmed:abstractText
Philadelphia-positive chronic myeloid leukemia (Ph+ CML) patients who are resistant to imatinib are commonly treated with second-generation tyrosine kinase inhibitors (TKIs). Limited data exist on the possible effects of these drugs on subsequent allogeneic hematopoietic stem cell transplantation (allo-HSCT).The outcome of 12 imatinib-resistant CML patients treated with dasatinib or nilotinib or both before allo-HSCT, was retrospectively analyzed. Patients were treated with second-generation TKIs for 1-17 months (median, 8). At the time of transplant, 3 patients were in complete cytogenetic response (CCgR), 3 patients in partial cytogenetic response (PCgR) and 6 patients were in less than PCgR. Donors were HLA-matched related in 4 cases and unrelated in 8 cases. Stem cell source was peripheral blood, bone marrow or cord blood in 6, 5 and 1 cases, respectively. All patients engrafted successfully and all but one achieved a full donor chimerism. Three patients experienced acute and chronic graft-versus-host disease. No cases of transplant-related mortality were recorded. Best response to allo-HSCT was complete molecular response (CMR) in 9 patients, major molecular response (MMR) in 1 patient and CCgR in 2 patients. Median follow-up was 16.5 months. At the last evaluation, 9 patients were in continuous CMR and 1 patient was in MMR; 2 patients had died of disease progression. Second-generation TKIs given before allo-HSCT do not negatively affect transplant engraftment and response rate, nor increases transplant-related toxicity.
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
1873-5835
pubmed:author
pubmed:copyrightInfo
Copyright 2009 Elsevier Ltd. All rights reserved.
pubmed:issnType
Electronic
pubmed:volume
34
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
143-7
pubmed:meshHeading
pubmed-meshheading:19481800-Adolescent, pubmed-meshheading:19481800-Adult, pubmed-meshheading:19481800-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:19481800-Drug Resistance, Neoplasm, pubmed-meshheading:19481800-Female, pubmed-meshheading:19481800-Hematopoietic Stem Cell Transplantation, pubmed-meshheading:19481800-Humans, pubmed-meshheading:19481800-Leukemia, Myelogenous, Chronic, BCR-ABL Positive, pubmed-meshheading:19481800-Male, pubmed-meshheading:19481800-Middle Aged, pubmed-meshheading:19481800-Piperazines, pubmed-meshheading:19481800-Protein Kinase Inhibitors, pubmed-meshheading:19481800-Pyrimidines, pubmed-meshheading:19481800-Remission Induction, pubmed-meshheading:19481800-Thiazoles, pubmed-meshheading:19481800-Transplantation, Homologous, pubmed-meshheading:19481800-Treatment Outcome, pubmed-meshheading:19481800-Young Adult
pubmed:year
2010
pubmed:articleTitle
Second-generation tyrosine kinase inhibitors before allogeneic stem cell transplantation in patients with chronic myeloid leukemia resistant to imatinib.
pubmed:affiliation
Department of Cellular Biotechnologies and Hematology, La Sapienza University, Rome, Italy. breccia@bce.uniroma1.it
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't, Multicenter Study